Last updated on December 2019

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies


Brief description of study

This is a Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD and clinical activity of AB928 in combination with AB122 in participants with advanced malignancies.

Detailed Study Description

Dose escalation of AB928 in combination with AB122 will be assessed in participants with advanced malignancies. In this dose escalation combination study participants will receive oral administration of AB928 as well as iv infusion of AB122.

Overall duration of treatment will depend on how well the treatment is tolerated. Treatment may continue until unacceptable toxicity or progressive disease or other reasons specified in the protocol.

Clinical Study Identifier: NCT03629756

Find a site near you

Start Over

Scottsdale, AZ

Scottsdale, AZ United States
  Connect »

Los Angeles, CA

Los Angeles, CA United States
  Connect »

Denver, CO

Denver, CO United States
  Connect »

Huntersville, NC

Huntersville, NC United States
  Connect »

San Antonio, TX

San Antonio, TX United States
  Connect »

Tyler, TX

Tyler, TX United States
  Connect »

Spokane, WA

Spokane, WA United States
  Connect »

Greenslopes, Australia

Greenslopes, Australia
  Connect »

Santa Monica

Santa Monica, CA United States
  Connect »

Ann Arbor

Ann Arbor, MI United States
  Connect »

Fort Worth

Fort Worth, TX United States
  Connect »

Los Angeles

Los Angeles, CA United States
  Connect »

Royal Oak

Royal Oak, MI United States
  Connect »